ArticleOncotarget2017
SORBS1 suppresses tumor metastasis and improves the sensitivity of cancer to chemotherapy drug.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Identification of cell adhesion-related subtypes and construction of risk model to predict breast cancer prognostic and immunological properties.World journal of surgical oncology · 2025Article
- BC-predict: mining of signal biomarkers and production of models for early-stage breast cancer subtyping and prognosis.Frontiers in bioinformatics · 2025Article
- A systems biology approach to unveil shared therapeutic targets and pathological pathways across major human cancers.Computational and structural biotechnology journal · 2025Article
- Integrating proteomics and machine learning reveals characteristics and risks of lymph node-independent distant metastasis in colorectal cancer.Frontiers in immunology · 2025Article
- GTF2H5 Identified as a crucial synthetic lethal target to counteract chemoresistance in colorectal cancer.Translational oncology · 2024Article
- Article
- Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.Cancers · 2024Review
- Liquid tumor microenvironment enhances WNT signaling pathway of peritoneal metastasis of gastric cancer.Scientific reports · 2023Article
- Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma.Cancer research · 2023Article
- Elevated ZNF704 expression is associated with poor prognosis of uveal melanoma and promotes cancer cell growth by regulating AKT/mTOR signaling.Biomarker research · 2023Article
- Down-regulation and clinical significance of Sorbin and SH3 domain-containing protein 1 in bladder cancer tissues.IET systems biology · 2023Article
- MiRZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- MicroRNA miR-3646 promotes malignancy of lung adenocarcinoma cells by suppressing sorbin and SH3 domain-containing protein 1 via the c-Jun NH2-terminal kinase signaling pathway.Bioengineered · 2022Article
- Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer.Journal of immunology research · 2022Article
- Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs.Theranostics · 2022Article
- Development and Validation of a Risk Prediction Model for Breast Cancer Prognosis Based on Depression-Related Genes.Frontiers in oncology · 2022Article
- Screening differentially expressed genes between endometriosis and ovarian cancer to find new biomarkers for endometriosis.Annals of medicine · 2021Article
- Tumor relevant protein functional interactions identified using bipartite graph analyses.Scientific reports · 2021Article
- Study on <em>CCDC69</em> interfering with the prognosis of patients with breast cancer through PPAR signal pathway.European journal of histochemistry : EJH · 2021Article
- Macrophage-derived EDA-A2 inhibits intestinal stem cells by targeting miR-494/EDA2R/β-catenin signaling in mice.Communications biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor metastasis and invasion are both hallmarks of cancer malignancy and the leading cause of cancer death. Here we show that the adaptor protein SORBS1 (Sorbin and SH3 domain-containing protein 1, also known as CAP/ponsin) is expressed at low levels in clinical cancer samples. In addition, low-level expression of SORBS1 was significantly associated with poor clinical outcomes and the increased tumor cell invasive capacity in breast cancer patients. We demonstrate that depletion of SORBS1 increases protrusions and filopodium-like protrusions (FLPs) formation, as well as the migratory and invasive abilities of cancer cells, via activation of JNK/cJun. Furthermore, silencing of SORBS1 promotes the epithelial-to-mesenchymal transition (EMT) process and attenuates chemical drug sensitivity especially that to cisplatin, by inhibition of p53 in breast cancer cells. Thus, we illustrate that SORBS1 is a potential inhibitor of metastasis in cancer and may be a promising target in chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.